维格列汀联合其他降糖药治疗2型糖尿病的疗效与安全性的Meta分析

摘要

Objective:To discuss Meta analysis of type 2 diabetes mellitus by Vildagliptin combined with other antidiabetic drug.Method:Through the retrieval of the Wanfang,Hownet,VIP and CBM database,type 2 diabetes mellitus,Vildagliptin,combination,hypoglycemic drugs,efficacy,safety were used as the keywords, Meta analysis into the literature were utilized,summarized the efficacy and safety of Vildagliptin combined with other antidiabetic drugs for the treatment of type 2 diabetes.Result:The literature through the screening of this study were included in the final 9 by Meta analysis showed that vildagliptin combination therapy was superior in terms of reducing glycated hemoglobin α-glucosidase inhibitors(P<0.05).From security point of view,the combination therapy slightly higher incidence of adverse reactions biguanide,sulfonylurea,glucagon-like peptide-1 receptor agonists and the incidence of hypoglycemia was no significant difference(P>0.05).Conclusion:Meta analysis showed that Vildagliptin in combination with other antidiabetic drugs to treat type 2 diabetes is not only effective and reliable,but also high security,it is worth of learning and using for reference.%目的：探讨2型糖尿病采取维格列汀联合其他降糖药治疗的疗效与安全性的Meta分析情况。方法：通过对万方、知网、维普、CBM等数据库进行检索，将2型糖尿病、维格列汀、联合、降糖药物、疗效、安全性等作为关键词，利用Meta分析纳入的文献，总结维格列汀联合其他降糖药物治疗2型糖尿病的疗效与安全性。结果：通过筛选后最终纳入本研究的文献研究有9个，经Meta分析显示维格列汀联合治疗在降低糖化血红蛋白方面优于α糖苷酶抑制剂（P<0.05）；安全性来看，联合治疗不良反应发生率稍高于双胍、磺脲类、胰高血糖素样肽1受体激动剂（GLP-1）等，而低血糖发生率比较差异无统计学意义（P>0.05）。结论：经Meta分析显示维格列汀联合其他降糖药物治疗2型糖尿病不仅疗效可靠，且安全性高，值得借鉴。